Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Scandinavian, Randomized, Rater-blinded Study of Single and Double-dose Betaferon in Patients With Early Secondary Progressive Multiple Sclerosis

Next Previous
X
Search
Trial Profile

A Scandinavian, Randomized, Rater-blinded Study of Single and Double-dose Betaferon in Patients With Early Secondary Progressive Multiple Sclerosis

Status: Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 07 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Interferon beta-1b (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms BECAUSE
  • Sponsors Bayer; Bayer HealthCare Pharmaceuticals

    • Most Recent Events

    • 31 Mar 2022 This trial has been completed in Denmark (Global end date: 15 Nov 2006).
    • 09 Mar 2015 Status changed from discontinued to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
    • 18 Dec 2008 Additional trial identifier (91449, EudraCT2005-001540-23) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top